NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading KROS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. KROS is currently loss-making and has a neutral management outlook, which adds uncertainty to its long-term thesis.
The valuation of KROS is considered cheap compared to its peers, with the market reflecting a justified expectations gap. There is low fragility in its pricing, indicating that the current market assumptions are stable.
Fundamentals may remain under pressure due to the elevated risk of an earnings miss in the near term. Recent financial performance has been neutral, and management's priorities show a focus on advancing clinical trials, but results have yet to translate into revenue.
The future performance of KROS hinges on the outcomes of its clinical trials and the performance of sector bellwethers like VRTX, REGN, and ARGX. Positive developments in these areas could provide support, while negative trends could lead to further challenges.
In the next 1-3 years, KROS faces a complex environment with both risks and opportunities. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Missing earnings could worry investors. This may raise concerns about money and funding.
Confirms:Next earnings report shows a larger loss than the last quarter's earnings miss.
Disproves:Next earnings report shows a smaller loss or a profit.
Why it matters: Updates on cash and capital needs will show if the company can sustain operations. Insufficient cash could lead to funding issues.
Confirms:Management says they have enough cash for operations until mid-2028.
Disproves:Management warns cash may run out sooner than expected.
Why it matters: Earnings results will show if cash levels remain stable and if losses are contained. This is crucial for funding future projects.
Confirms one read:Q2 2026 earnings report shows a net loss less than $23.7 million.
Confirms the other:Q2 2026 earnings report shows a net loss greater than $23.7 million.
Why it matters: If the health care sector shows renewed growth, it could boost Keros' prospects. This would indicate a favorable market environment.
Confirms:Health care sector revenue growth accelerates back toward 15% year over year.
Disproves:Health care sector revenue growth remains below 5% year over year.
Why it matters: Funding plans are crucial for sustaining operations. It affects investor confidence and future growth.
Confirms:Watch for updates on funding or new financing from management.
Disproves:Watch for no updates or bad news about funding being enough.
Why it matters: Starting this trial would show progress in Keros' partnership with Takeda. It could lead to new revenue streams.
Confirms:A press release says the Phase 3 trial for elritercept in myelofibrosis has started.
Disproves:No announcement of trial initiation by the end of Q3 2026.
Why it matters: Updates on this trial will indicate if Keros is advancing its pipeline as planned. This is key for investor confidence.
Confirms:A press release announcing the start or progress of the Phase 2 trial for KER-065 in DMD patients.
Disproves:No updates or delays reported on the Phase 2 trial by the end of Q3 2026.
